Lifeboat Foundation

And inflammation is one of the three primary ageing processes.

Scientists have discovered a new metabolic process in the body that can switch off inflammation. They have discovered that ‘itaconate’—a molecule derived from glucose—acts as a powerful off-switch for macrophages, which are the cells in the immune system that lie at the heart of many inflammatory diseases including arthritis, inflammatory bowel disease and heart disease.

The scientists, working in the School of Biochemistry and Immunology in the Trinity Biomedical Sciences Institute at Trinity College Dublin, hope their discovery will have relevance for inflammatory and infectious diseases—and that their findings may also help to develop much-needed new drugs to treat people living with these conditions.

Professor of Biochemistry at Trinity, Luke O’Neill, was, along with Dr. Mike Murphy of the University of Cambridge, the joint leader of the work just published in leading international journal Nature. The discoveries were made using both human cells and mice as a model organism.

Continue reading “Scientists discover promising off-switch for inflammation” »

Hats off to scientists that keep finding novel methods to fight cancer.

The ever increasing research in cancer cure has led to the market growth of a popular new solution — Antibody-drug conjugates.

The researchers found that when taking the supplement, dilation of subjects’ arteries improved by 42 percent, making their blood vessels, at least by that measure, look like those of someone 15 to 20 years younger.

Excess reactive oxygen species production by mitochondria is a key mechanism of age-related vascular dysfunction. Our laboratory has shown that supplementation with the mitochondrial-targeted antioxidant MitoQ improves vascular endothelial function by reducing mitochondrial reactive oxygen species and ameliorates arterial stiffening in old mice, but the effects in humans are unknown. Here, we sought to translate our preclinical findings to humans and determine the safety and efficacy of MitoQ. Twenty healthy older adults (60–79 years) with impaired endothelial function (brachial artery flow–mediated dilation 6%) underwent 6 weeks of oral supplementation with MitoQ (20 mg/d) or placebo in a randomized, placebo-controlled, double-blind, crossover design study.

https://www.mindpodnetwork.com/future-fossils-72-ira-pastor-…animation/

BGN Technologies, the technology-transfer company of Ben-Gurion University of the Negev (BGU), announced that a research group led by Prof. Varda Shoshan-Barmatz of the BGU Department of Life Sciences and the National Institute for Biotechnology in the Negev, is developing a new molecule to treat cancer that inhibits cancer cell growth and changes these cells back to normal ones.

“Although this is in the early stages, we are excited with results that demonstrate this novel molecule’s potential for cancer treatment,” says Prof. Shoshan-Barmatz. “Basically, we’ve discovered a code for reprograming cancer cells that causes them to lose their oncogenic features.”

The novel treatment is based on siRNA (small interfering ribonucleic acid), which silences expression of the mitochondrial gatekeeper protein, VDAC1. This protein is highly overexpressed in many solid and non-solid tumors and is crucial for supplying the high energy demands of malignant cells.

The World Health Organization is preparing for the “worst-case scenario” as it continues to respond to the Ebola outbreak in the Democratic Republic of Congo.

Peter Salama, deputy director-general of emergency preparedness and response at the WHO, said in Geneva, Switzerland, on Friday that it’s “going to be tough and it’s going to be costly to stamp out this outbreak.”

There have been 34 cases of Ebola virus disease reported during the past five weeks, the WHO said Friday. Of those, two have been confirmed using laboratory tests, 14 are suspected, and 18 — who are deceased — are considered probable for the disease. Three of the patients are health care workers.

Continue reading “WHO preparing for ‘worst-case scenario’ in Ebola outbreak” »

A team of researchers at the University of Texas has found NAD+ synthesis and consumption integrate glucose metabolism and adipogenic transcription during adipocyte differentiation. In their paper published in the journal Science, the group describes their research into how glucose is converted into fat in the body and what they found. Sophie Trefely and Kathryn Wellen with the University of Pennsylvania and Drexel University, respectively, offer a Perspective piece on the work done by the team in Texas in the same journal issue.

As obesity rates continue to climb around the globe, scientists continue to explore why it is happening. In addition to studying the psychological aspects involved, scientists would also like to better understand why eating too much makes people gain weight. In this new effort, the researchers looked more closely into why consuming too much glucose causes the body to produce fat.

Prior research has shown that nicotinamide adenine dinucleotide (NAD) is an important molecule that plays a role in a wide variety of physiological and pathological processes. Its oxidized form, NAD+, has also been found to act as a cofactor in metabolic pathways, and more importantly, perhaps, is consumed by various enzymes. Once consumed, NAD+ is broken down into nicotinamides and ADP-ribose. This, the researchers note, means that NAD+ must be resynthesized for normal cellular function to continue. They further note that some prior research has suggested that lower-than-normal levels of NAD+ can alter metabolism, leading in some cases to higher disease susceptibility.

Continue reading “Researchers find glycolysis links to gene transcription via NAD+” »

A discussion on whether or not extended lifespans might make us paranoid about every tiniest risk.

Some months back, I read “Sapiens: A Brief History of Humankind” by Yuval Noah Harari. It’s a really good book, though it did disappoint me significantly when, after discussing the past and the present of our species, the author began glancing towards possible futures. At that point, the impartiality required of a historian, which Harari had thus far managed to keep up more or less evenly throughout the book, gave way to a subtly implied pessimism pervading, among other things, his views on future rejuvenation biotechnology.

Honestly, I wasn’t expecting him to even touch upon the subject; I was pleasantly surprised, at least until I realized that his concerns, most of which were the usual ones you’d expect, seemed to make him inclined to see rejuvenation as a plague rather than a blessing.

Continue reading “On life extension and risk aversion” »

Sutton et al. conduct the first supervised controlled feeding trial to test whether intermittent fasting has benefits in humans in the absence of weight loss. Prediabetic men following a form of intermittent fasting called early time-restricted feeding improved their insulin sensitivity, blood pressure, and oxidative stress levels without losing weight.